Comerica Bank lowered its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 1.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 96,301 shares of the medical instruments supplier’s stock after selling 975 shares during the period. Comerica Bank’s holdings in Becton Dickinson and were worth $17,579,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Novare Capital Management LLC increased its position in Becton Dickinson and by 14.0% in the first quarter. Novare Capital Management LLC now owns 26,534 shares of the medical instruments supplier’s stock valued at $4,867,000 after buying an additional 3,260 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in Becton Dickinson and by 511.0% in the first quarter. BNP Paribas Arbitrage SA now owns 183,874 shares of the medical instruments supplier’s stock valued at $33,730,000 after buying an additional 153,780 shares in the last quarter. Suntrust Banks Inc. increased its position in Becton Dickinson and by 0.8% in the first quarter. Suntrust Banks Inc. now owns 27,187 shares of the medical instruments supplier’s stock valued at $4,985,000 after buying an additional 229 shares in the last quarter. Family Firm Inc. bought a new position in Becton Dickinson and during the first quarter valued at $221,000. Finally, Harbour Investment Management LLC bought a new position in Becton Dickinson and during the first quarter valued at $2,148,000. 82.30% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Becton Dickinson and Co (NYSE:BDX) opened at 192.59 on Thursday. The firm has a 50-day moving average price of $185.36 and a 200 day moving average price of $178.43. Becton Dickinson and Co has a 12 month low of $161.29 and a 12 month high of $194.11. The company has a market cap of $41.08 billion, a P/E ratio of 31.99 and a beta of 1.00.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, May 2nd. The medical instruments supplier reported $2.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.23 by $0.07. Becton Dickinson and had a return on equity of 25.25% and a net margin of 10.54%. The business had revenue of $2.97 billion during the quarter, compared to the consensus estimate of $2.92 billion. During the same period in the previous year, the business earned $2.18 EPS. The business’s quarterly revenue was down 3.2% on a year-over-year basis. Equities research analysts predict that Becton Dickinson and Co will post $9.44 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, June 30th. Stockholders of record on Friday, June 9th will be issued a $0.73 dividend. This represents a $2.92 annualized dividend and a dividend yield of 1.52%. The ex-dividend date is Wednesday, June 7th. Becton Dickinson and’s payout ratio is currently 48.42%.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/06/08/comerica-bank-has-17-58-million-stake-in-becton-dickinson-and-co-bdx.html.

Several equities analysts have recently weighed in on the company. Zacks Investment Research downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Evercore ISI raised Becton Dickinson and from an “in-line” rating to an “outperform” rating and boosted their target price for the company from $186.00 to $200.00 in a research report on Monday, April 24th. Royal Bank of Canada reissued a “hold” rating and set a $177.00 target price on shares of Becton Dickinson and in a research report on Thursday, April 13th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $200.00 target price on shares of Becton Dickinson and in a research report on Wednesday, March 29th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $186.09.

In other news, VP Jeffrey S. Sherman sold 28,765 shares of the business’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $185.98, for a total value of $5,349,714.70. Following the completion of the sale, the vice president now directly owns 70,821 shares of the company’s stock, valued at approximately $13,171,289.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.40% of the stock is currently owned by insiders.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Receive News & Ratings for Becton Dickinson and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Co and related companies with MarketBeat.com's FREE daily email newsletter.